The grant provides modest non-dilutive funding for AI development but does not change the company's near-term revenue outlook. Monitor for clinical validation results and commercial adoption of the SmartScan AI platform, as well as upcoming quarterly financials for cash runway updates.
Price Chart
Executive Summary
Pulsenmore announced a $1.27 million grant from the Israel Innovation Authority for its SmartScan AI program, its second AI grant within a month, bringing total AI grants to approximately $1.6 million. The non-dilutive funding supports R&D for AI-powered home ultrasound guidance, but the company remains pre-revenue with no financial results reported in this filing. The news is a modest positive for the company's AI strategy but lacks near-term revenue impact, warranting a neutral sentiment with low impact given the small grant size relative to development costs and the forward-looking nature of the program.
Key Facts
- Israel Innovation Authority approved a $1.27 million grant for the SmartScan AI program.
- Total AI grants approved over the past month are approximately $1.6 million, supporting two programs with a combined scope of ~$3.12 million.
- The 12-month SmartScan AI program aims to develop AI-powered real-time ultrasound analysis and dynamic guidance for home use.
- Development will draw on data from more than 250,000 clinical scans accumulated on the company's platform.
- This is the second AI grant from the Israel Innovation Authority within one month, following a July 2026 grant for clinical workflow AI.
Financial Impact
Non-dilutive grant of $1.27 million for R&D; total AI grants ~$1.6 million. No revenue or earnings impact reported.
Risk Factors
- SmartScan AI is in early development and may not achieve technical or clinical milestones.
- The company has no operating history of generating revenue from AI-powered products.
- Forward-looking statements about scaling home ultrasound are subject to significant execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-038623 |
| Exhibit: ex99-1.htm | 0001493152-26-038623 |
| Document: 0001493152-26-038623-index-headers.html | 0001493152-26-038623 |
| Document: 0001493152-26-038623-index.html | 0001493152-26-038623 |
| Document: 0001493152-26-038623.txt | 0001493152-26-038623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.90 | awaiting T+20 | — | $1.77 (−6.84%) |
Oct 8, 2026 18d ago | SC 13G | $1.85 | awaiting T+20 | — | $1.77 (−4.32%) |
Sep 17, 2026 5w ago | 6-K | $2.42 $1.81 | ▼ −25.21% | ▼ −26.41% | $1.77 (−26.86%) |
Sep 8, 2026 6w ago | 6-K | $2.46 $2.16 | ▼ −12.20% | ▼ −13.91% | $1.77 (−28.05%) |
Sep 2, 2026 7w ago | EFFECT | $2.55 $2.22 | ▲ +12.94% | ▲ +12.86% | $1.77 (+30.59%) |
Aug 31, 2026 8w ago | 6-K | $2.62 $2.19 | ▼ −16.41% | ▼ −16.22% | $1.77 (−32.44%) |
Aug 19, 2026 9w ago | 6-K | $3.01 $2.42 | ▼ −19.60% | ▼ −18.76% | $1.77 (−41.20%) |
Aug 17, 2026 10w ago | 6-K | $2.89 $2.41 | ▼ −16.61% | ▼ −14.63% | $1.77 (−38.75%) |
Jul 13, 2026 15w ago | 6-K | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.77 (−51.10%) |
Jul 13, 2026 15w ago | EFFECT | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.77 (−51.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers